---
title: dFDA Calculation Framework - NPV Methodology
description: Detailed calculation framework for NPV analysis including costs, savings, and ROI methodology
lastToneElevationWithHumorHash: 6a8a0ba36fb56b9eb85d5fe126ee3b02d6a37708dc2e02198caa95f20400866d
lastInstructionalVoiceHash: add6ecffe2d6d2464c5cdc0ef6f7d8c99a3b4ad15b644c11b99e2bca8efc2cd1
---

```{python}
#| echo: false
import sys
import os

# Quarto executes from project root (execute-dir: project in _book.yml)

appendix_path = os.path.join(os.getcwd(), 'brain', 'book', 'appendix')
if appendix_path not in sys.path:
    sys.path.insert(0, appendix_path)

from economic_parameters import *
```


Below is an illustrative framework with more formal equations and a simplified but "rigorous" model to analyze the cost–benefit dynamics and ROI of upgrading the FDA (and analogous global regulators) into a decentralized, continuously learning platform. Many real-world complexities (e.g., drug-specific risk profiles, variable regulatory timelines across countries) would require further refinement, but these equations give a starting point for a more quantitative analysis.

#### Definitions and Parameters

You define the following parameters to capture costs, savings, timelines, and scaling/adoption:

1. **Initial (Upfront) Costs**

   $$
     C_0 = C_{\text{tech}} + C_{\text{blockchain}} + C_{\text{data}} + C_{\text{legal}}
   $$

   - $C_{\text{tech}}$: Core platform development (software, AI, UI/UX).
   - $C_{\text{blockchain}}$: Blockchain or other distributed-ledger infrastructure.
   - $C_{\text{data}}$: Integration with EHRs, wearables, privacy/security frameworks.
   - $C_{\text{legal}}$: Harmonizing global regulations and legal frameworks.

2. **Annual Operating Costs** (in year $t$):

   $$
     C_{\text{op}}(t) = C_{\text{maint}}(t) + C_{\text{analysis}}(t) + C_{\text{admin}}(t) + C_{\text{participant}}(t)
   $$

   - $C_{\text{maint}}(t)$: Ongoing software maintenance, hosting, cybersecurity.
   - $C_{\text{analysis}}(t)$: Machine learning, data processing, and analytics costs.
   - $C_{\text{admin}}(t)$: Lean administrative overhead, compliance checks, auditing.
   - $C_{\text{participant}}(t)$: Compensation or incentives for trial participation.

3. **Trial Costs Under Traditional vs. Decentralized Models**

   - Let $x$ be the number of patients in a given trial.
   - **Traditional cost per patient**: $c_{t}$.
   - **Decentralized cost per patient**: $c_{d}$, where $c_{d} \ll c_{t}$.

   Therefore, the total cost for a single trial of size $x$ is:

   $$
     \text{Cost}_{\text{traditional}}(x) = c_{t} \cdot x
   $$

   $$
     \text{Cost}_{\text{decentralized}}(x) = c_{d} \cdot x
   $$

   The per-trial savings for $x$ patients is then:

   $$
     S_{\text{trial}}(x) = c_{t} x - c_{d} x = (c_{t} - c_{d})x
   $$

4. **Industry-Wide R&D Spend & Adoption**

   - Let $R_{d}$ be the **annual global R&D expenditure** on clinical trials (baseline).
   - Let $\alpha \in [0,1]$ be the **fraction of R&D cost that can be saved** when trials shift to the decentralized model (this encompasses both per-patient cost savings and administrative/overhead reductions).
   - Let $p(t)\in [0,1]$ be the **fraction of industry adoption** at year $t$. Early on, $p(t)$ may be low; over time, it might approach 1 if the platform becomes standard worldwide.

   Thus, the **annual cost savings** in year $t$ from using the decentralized model is approximated by:

   $$
     S(t) = p(t)\alpha R_{d}
   $$

   (This expression assumes full feasibility for all relevant trials and that the fraction $\alpha$ is the average cost reduction across all trials.)

5. **Discount Rate & Net Present Value**

   - Let $r$ be the **annual discount rate** (e.g., 5–10% for cost-of-capital or social discounting).
   - A future cost (or saving) in year $t$ is discounted by $\frac{1}{(1 + r)^t}$.

#### NPV of Costs

You sum the upfront cost $C_{0}$ and the net present value (NPV) of ongoing operational costs $C_{\text{op}}(t)$ from $t = 1$ to $t = T$:

$$
  \text{NPV}(\text{Costs})
  = C_{0}
    + \sum_{t=1}^{T} \frac{C_{\text{op}}(t)}{(1 + r)^t}
$$

#### NPV of Savings

Using your adoption model $p(t)$ and fraction of R&D spend $\alpha$ that is saved, the annual savings is $S(t) = p(t)\alpha R_{d}$. Over $T$ years, the total NPV of these savings is:

$$
  \text{NPV}(\text{Savings})
  = \sum_{t=1}^{T} \frac{S(t)}{(1 + r)^t}
  = \sum_{t=1}^{T} \frac{p(t)\alpha R_{d}}{(1 + r)^t}
$$

_Note_: If the adoption curve $p(t)$ grows over time, you might model it with an S-shaped or logistic function. For instance:

$$
  p(t) = \frac{1}{1 + e^{-k(t - t_{0})}}
$$

where $k$ is the steepness of adoption and $t_{0}$ is the midpoint.

#### ROI

You define ROI as the ratio of the **NPV of total savings** to the **NPV of total costs**:

$$
  \text{ROI}
  = \frac{\text{NPV}(\text{Savings})}{\text{NPV}(\text{Costs})}
  = \frac{\sum_{t=1}^{T} \frac{p(t)\alpha R_{d}}{(1 + r)^t}}
         {C_{0} + \sum_{t=1}^{T} \frac{C_{\text{op}}(t)}{(1 + r)^t}}
$$

Alternatively, one might define a _net_ ROI (or net benefit) as:

$$
  \text{Net Benefit}
  = \text{NPV}(\text{Savings}) - \text{NPV}(\text{Costs})
$$

If $\text{Net Benefit} > 0$, the program yields a positive return in present-value terms.

#### Example Parameterization

For a concrete (though simplified) scenario, assume:

1. **Upfront Costs** ($C_0$):

   $$
     C_0 = 0.26975 \text{ billion USD}
   $$

   _(This represents an estimated cost for initial core platform build (see [Upfront (Capital) Expenditure](#upfront-capital-expenditure-initial-build-illustrative-30-months)), foundational broader initiative setup, and early legal/regulatory framework alignment (see medium case upfront costs in [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs)), consistent with multi-year funding such as in the ["Right to Trial and FDA Upgrade Act"](right-to-trial-fda-upgrade-act.qmd) for the FDA v2 platform. This combined figure is distinct from the core platform build ROM alone and serves as an illustrative figure for this NPV example that is lower than the previous $3B placeholder.)_

2. **Annual Operating Costs** ($C_{\text{op}}(t)$):

   $$
     C_{\text{op}}(t) = 0.04005 \text{ billion USD (constant)}
   $$

   _(This figure is also explicitly derived from the ROM estimates. It represents the sum of the midpoint of the Annual Core Platform Operations from [Annual Operational Costs](#annual-operational-costs-illustrative-at-target-scale-of-5m-mau-50tb-ingest-month) (~\$18.75M) and the Medium Case annual costs for Broader Initiatives from [Scenario-Based ROM Estimates](#scenario-based-rom-estimates-for-broader-initiative-costs) (~\$21.3M). This excludes large-scale, direct participant compensation programs which would be funded separately, as discussed in Annual Operational Costs.)_

3. **Annual Global R&D Spend** ($R_d$):
   $$
     R_d = 100 \text{ billion USD}
   $$
   _([See Market Size and Impact](#market-size-and-impact))_

4. **Fraction of R&D Cost Saved** ($\alpha$):
   $$
     \alpha = 0.50 \quad (50\% \text{ average reduction})
   $$
   (This is conservative relative to some references suggesting up to [80× savings](#decentralized-trial-costs-modeled-on-oxford-recovery). It's important to note that these projected R&D savings are achieved not only through the inherent technical and operational efficiencies of decentralized, platform-based trials, e.g., reduced site management, automated data capture, but also through the anticipated competitive pressures the transparent dFDA Infrastructure will place on sponsors to optimize trial designs and submit lean, competitive operational cost estimates. [See Gross R and D Savings](#gross-r-and-d-savings-from-dfda-implementation).)\*

5. **Adoption Curve** ($p(t)$):

   - Suppose a ramp from 0% adoption at $t=0$ to 100% by $t=5$. One simple linear approach is:
     $$
       p(t) = \frac{t}{5} \quad \text{for } 0 \le t \le 5
     $$
     and $p(t) = 1$ for $t > 5$.

6. **Discount Rate** ($r$):
   $$
     r = 0.08 \quad (8\%)
   $$

7. **Time Horizon** ($T$):
   $$
     T = 10 \text{ years}
   $$

##### NPV of Costs

$$
  \text{NPV}(\text{Costs})
  = C_0
  + \sum_{t=1}^{10} \frac{C_{\text{op}}(t)}{(1 + r)^t}
$$

- Upfront: $C_0 = 0.26975$.
- Each year: $C_{\text{op}}(t) = 0.04005$.

Hence,

$$
  \text{NPV}(\text{Costs})
  = 0.26975
  + \sum_{t=1}^{10} \frac{0.04005}{(1 + 0.08)^t}
$$

A standard annuity formula:

$$
  \sum_{t=1}^{10} \frac{1}{(1+0.08)^t}
  = \frac{1 - (1.08)^{-10}}{0.08}
  \approx 6.71008
$$

Therefore,

$$
  \sum_{t=1}^{10} \frac{0.04005}{(1+0.08)^t}
  = 0.04005 \times 6.71008
  \approx 0.2687
$$

So,

$$
  \text{NPV}(\text{Costs})
  \approx 0.26975 + 0.2687
  = 0.53845 \text{ (billion USD)}
$$

##### NPV of Savings

$$
  S(t) = p(t)\alpha R_d
        = p(t) \times 0.50 \times 100
        = 50p(t)
$$

For $t=1$ to 5, $p(t) = t/5$. For $t=6$ to 10, $p(t) = 1$.

1. **Years 1–5**:
   $$
     S(t) = 50 \times \frac{t}{5} = 10t
   $$

2. **Years 6–10**:
   $$
     S(t) = 50
   $$

Hence,

$$
  \text{NPV}(\text{Savings})
  = \sum_{t=1}^{10} \frac{S(t)}{(1.08)^t}
  = \sum_{t=1}^{5} \frac{10t}{(1.08)^t}
    + \sum_{t=6}^{10} \frac{50}{(1.08)^t}
$$

Let's approximate numerically:

- For $t=1$ to 5:
  - $t=1$: $S(1) = 10$. Discount factor: $\frac{1}{1.08}\approx 0.9259$. Contribution: $10 \times 0.9259=9.26$.
  - $t=2$: $S(2) = 20$. Discount factor: $\frac{1}{1.08^2}\approx 0.8573$. Contribution: $20 \times 0.8573=17.15$.
  - $t=3$: $S(3) = 30$. Factor: $\approx 0.7938$. Contribution: $23.81$.
  - $t=4$: $S(4) = 40$. Factor: $\approx 0.7350$. Contribution: $29.40$.
  - $t=5$: $S(5) = 50$. Factor: $\approx 0.6806$. Contribution: $34.03$.

  Summing these: $9.26 + 17.15 + 23.81 + 29.40 + 34.03 \approx 113.65$.

- For $t=6$ to 10, $S(t)=50$. Each year's discount factor:
  - $t=6$: $\approx 0.6302$. Contribution: $31.51$.
  - $t=7$: $\approx 0.5835$. Contribution: $29.17$.
  - $t=8$: $\approx 0.5403$. Contribution: $27.02$.
  - $t=9$: $\approx 0.5003$. Contribution: $25.02$.
  - $t=10$: $\approx 0.4632$. Contribution: $23.16$.

  Summing these: $31.51 + 29.17 + 27.02 + 25.02 + 23.16 \approx 135.88$.

Thus,

$$
  \text{NPV}(\text{Savings})
  \approx 113.65 + 135.88
  = 249.53 \text{ (billion USD)}
$$

##### Final ROI and Net Benefit

$$
  \text{ROI}
  = \frac{249.53}{0.53845}
  \approx 463.4
  \quad (\text{i.e., about } `[{python} format_roi(ROI_DFDA_SAVINGS_ONLY)]`)
$$

$$
  \text{Net Benefit}
  = 249.53 - 0.53845
  = 248.99155 \text{ (billion USD)}
$$

In this rough example, even **partial adoption** in the early years delivers large returns. If $\alpha$ or $p(t)$ were higher, or if the discount rate $r$ were lower, the ROI would increase further. _This ROI is based on a cost model that is now explicitly derived from the detailed component estimates in the ['Costs of Building and Operating the Global Decentralized FDA ROM Estimate'](#costs-of-building-and-operating-the-global-decentralized-fda-rom-estimate) section, providing a more transparent and verifiable result._

#### Other Extensions and Considerations

1. **Time-to-Market Acceleration**  
   One can add a parameter $\Delta t$ for the number of years of early market entry. Earlier entry can yield extra revenue or extend effective patent life. A simplified approach might add a term for the "additional value" of each year gained:

   $$
     V_{\Delta t} = \gamma \Delta t
   $$

   where $\gamma$ is the annual net cash flow gained from earlier commercialization. This can be factored into $\text{NPV}(\text{Savings})$.

2. **Value of Testing More Candidates**  
   Reductions in per-trial costs might **double** or **triple** the number of drug candidates tested each year, including off-label indications, nutraceuticals, and personalized therapies. One could introduce a function:

   $$
     N'(t) = \beta \cdot N(t)
   $$

   where $N(t)$ is the baseline number of trials (or new drug approvals) per year, and $\beta > 1$ reflects the increased throughput. The incremental societal or commercial value of these additional approvals can be added to the savings side of the equation.

3. **Quality-Adjusted Life Years (QALYs)**  
   For a more health-economic model, incorporate a **health outcomes** dimension, e.g., QALYs gained from earlier availability of better therapies, or from broader real-world evidence that improves prescribing practices. This would create a cost–utility analysis with:

   $$
   \text{Net Monetary Benefit} = \lambda \times \Delta \text{QALYs} - \text{NPV}(\text{Costs})
   $$

   where $\lambda$ is the willingness-to-pay per QALY.

4. **Risk & Uncertainty**

   - Real-world constraints (regulatory pushback, privacy laws) might reduce $\alpha$.
   - Slower adoption or partial global integration might reduce $p(t)$.
   - Incremental infrastructure costs might be higher if existing EHR systems are fragmented.

Even so, the core takeaway remains: **If the platform is widely adopted and per-patient trial costs drop substantially, the net benefits likely dwarf the initial investments.**

---
